drugset / Trial / NCT01906801

Clinical Efficacy of Glucosamine Plus Diacerein Versus Mono-therapy of Glucosamine

NCT01906801

Phase 4 Completed 148 enrolled Ramathibodi Hospital
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare pain scores, WOMAC total and subscores, actual and change of joint space width and the rate of gastrointestinal side effects at 4, 8, 12, and 24 weeks between dual-therapy of diacerein and glucosamine versus a mono-therapy of glucosamine in OA patients

Timeline

Start
2013-07
Primary completion
2014-10
Completion
2014-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Diacerein Small molecule 50 mg Oral
Subject Glucosamine Small molecule 1500 mg Oral

Indications